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serving as a precursor not only in protein synthesis and the urea
cycle but also in the generation of polyamines, creatine and nitric
oxide (NO). In the context of metabolic syndrome and inﬂamma-
tory diseases, the conversion of arginine to NO and citrulline by
NO synthases (NOS) and also its conversion to ornithine and urea
by arginases have been of special interest. Research has focused
in particular on two enzyme isoforms, inducible NOS (iNOS)
and arginase 1. Induction of iNOS is a hallmark of classically acti-
vated (M1) macrophages and type 1 T helper (Th1) cell responses
with iNOS producing oxidative stress, thus promoting anti-
pathogen responses [1,2] but also metabolic disorders, such as
insulin resistance [3]. Arginase 1 is a key marker of alternatively
activated (M2) macrophages, which confer anti-inﬂammatory
properties by substrate competition with iNOS and through other
mechanisms [4–6]. Interestingly, macrophages and dendritic cells
express also the second arginase isoform, arginase 2, a predomi-
nantly mitochondrial protein [4,7,8]. Arg1 and Arg2 knockout
mice have been instrumental in understanding the in vivo roles
of arginases. As the total deﬁciency of arginase 1, an essential
urea cycle enzyme, is postnatally lethal, most studies have used
arginase 2 deﬁcient mice (Arg2/) [9]. The role of arginase 2 in
inﬂammation is, however, less well understood.
In this issue, the Journal of Hepatology publishes an interesting
study by Navarro et al. [10]. The authors describe a phenotype of
spontaneous steatohepatitis in Arg2/ mice on a chow diet,
which is aggravated after feeding a high fat diet. As underlying
mechanisms the authors identify hepatic upregulation of genes
and proteins associated with de novo lipogenesis, increased hepa-
tic recruitment of F4/80-positive macrophages, and an increased
hepatic expression of inﬂammatory genes, especially iNOS and
IL-1b, in Arg2/ mice.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.This ﬁnding is remarkable, as arginase 2 is not expressed in
hepatocytes but rather in extra-hepatic organs, such as intestine
and kidney as well as in macrophages and dendritic cells [4–8].
Depletion of hepatic, but not of adipose tissue macrophages by
clodronate at least partially reversed the induction of lipogenic
genes and hepatic steatosis that were observed in Arg2/ mice.
This led the authors to the interpretation that hepatic macro-
phages are pivotal for hepatic steatogenesis in Arg2/ mice.
The classical multiple-hit theory of NASH pathogenesis identi-
ﬁes macrophages as mediators of the transition from steatosis to
steatohepatitis, responding to inﬂammatory second hits, the ﬁrst
hit being hepatocellular lipid accumulation [11]. This concept is
increasingly being challenged. Several recent studies have identi-
ﬁed liver macrophages as promoters not only of inﬂammation in
NASH but also of hepatic lipogenesis and lipid accumulation: two
studies have demonstrated that depletion of hepatic macro-
phages prevents obesity-induced hepatic steatosis in rodents.
Both studies postulate an inﬂuence of macrophage-derived
cytokines on hepatocellular lipid metabolism, resulting in hepa-
tocellular lipid accumulation. While Huang et al. identify TNF-a
as a mediator of this macrophage-hepatocyte crosstalk, the study
by Negrin et al. convincingly demonstrates that hepatocellular
lipogenesis is induced by IL-1b, conﬁrming ﬁndings of an earlier
paper, which has identiﬁed IL-1b as a promoter of experimental
NASH progression [12–14]. In line with these studies, the paper
by Navarro et al. suggests that macrophages have the potential
to deliver the ‘‘ﬁrst hit’’ in the pathogenesis of NASH by inducing
hepatocellular lipid accumulation. One could speculate that Arg2
deﬁciency creates a macrophage phenotype with a lipogenesis-
inducing cytokine signature. More work is warranted to conﬁrm
the role of liver macrophages/Kupffer cells in Arg2 deﬁciency-
mediated liver steatosis and inﬂammation. Bone marrow trans-
plantation experiments using Arg2/ donors, or tissue speciﬁc
knockouts, would be a suitable way to address these questions.
Moreover, it will be an interesting challenge to identify stea-
togenic mediators, secreted from Arg2/ macrophages, a likely
candidate being IL-1b, which was strongly upregulated in the
livers of Arg2/ mice. Identifying the downstream signalling
events in hepatocytes will be equally important. These could
be, for example, increased endoplasmic reticulum stress resulting
in SREBP1c activation [15] or oxidative stress generated by iNOS.
iNOS is expressed in hepatocytes as well as liver macrophages15 vol. 62 j 260–261
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and has been shown to be involved in the development of NAFLD
in mice, provoked by high fructose feeding [16].
The ﬁndings by Navarro et al. emphasize that lack of arginase
2 promotes NASH progression, implying a therapeutic potential
of sustained arginase 2 activity. However, studies of arginase 2
in atherosclerosis models caution against translational enthusi-
asm. Two papers describe a pro-inﬂammatory role of arginase 2
in macrophages, connecting arginase 2 with the inﬂammatory
macrophage M1 phenotype [4,5]. Strikingly, Arg2 deﬁciency pro-
tected apolipoprotein E-knockout mice from atherosclerotic
lesions [5]. These ﬁndings apparently contradict the data by Nav-
arro et al. who claim that Arg2-deﬁcient macrophages display an
M1 phenotype. However, it has to be taken into consideration
that a detailed characterization of liver macrophages was not
the focus of this study, and interpretation was based on the inﬂu-
ence of arginase 2 on inﬂammatory gene expression in whole
liver tissue. The divergent data from these studies suggest that
effects of arginase 2 on macrophage function could be tissue or
organ speciﬁc.
The study by Navarro et al. provokes the question if an altered
arginase 2 activity, or more generally arginine availability, is rel-
evant in human NASH. While in Arg2/ mice elevated arginine
levels and NASH were described [9,10], several arginine supple-
mentation studies suggest that increasing systemic arginine lev-
els can be beneﬁcial. Insulin resistant subjects and cardiovascular
patients, chronically supplemented with arginine, exhibited sig-
niﬁcantly improved glucose homeostasis and vascular functions
[17–19]. Similarly, studies have demonstrated favourable effects
of arginase inhibitors on endothelial function, mostly attributed
to increased NO availability for endothelial NO synthase [20]. In
light of the study by Navarro et al., it will be important to perform
arginine supplementation and arginase inhibitor studies,
addressing NAFLD. Taken together, although the current and pre-
vious ﬁndings suggest that the net biological effects of arginase 2
are context and tissue speciﬁc, arginase modulation still seems to
offer many therapeutic implications. Future research is war-
ranted to further explore the fascinating, multi-facetted role of
arginine metabolism on NAFLD in the context of the metabolic
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